

# Emre Bilgin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3477739/publications.pdf>

Version: 2024-02-01

95  
papers

412  
citations

1040056

9  
h-index

794594

19  
g-index

97  
all docs

97  
docs citations

97  
times ranked

724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Behçet Disease With Vascular Involvement. <i>Medicine (United States)</i> , 2015, 94, e494.	1.0	114
2	Increased cancer risk in patients with periodontitis. <i>Current Medical Research and Opinion</i> , 2017, 33, 2195-2200.	1.9	38
3	Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). <i>BMC Public Health</i> , 2019, 19, 487.	2.9	33
4	Comparing polyarteritis nodosa in children and adults: a single center study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1016-1022.	1.9	30
5	Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study. <i>Clinical Rheumatology</i> , 2019, 38, 1699-1706.	2.2	18
6	Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 675-676.	0.9	17
7	PILE: a candidate prognostic score in cancer patients treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1630-1636.	2.4	14
8	Increased psoriasis frequency in patients with familial Mediterranean fever. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 57-61.	0.9	11
9	The association of various social capital indicators and physical activity participation among Turkish adolescents. <i>Journal of Sport and Health Science</i> , 2018, 7, 27-33.	6.5	11
10	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 297-308.	0.9	11
11	Proposal of a new nomenclature for the underlying pathogenetic mechanism of severe Coronavirus Disease-19: "Inflammatory Thrombosis with Immune Endotheliitis". <i>Rheumatology International</i> , 2021, 41, 679-680.	3.0	10
12	Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 105-108.	0.6	9
13	Poor outcomes among elderly patients hospitalized for influenza-like illness. <i>Current Medical Research and Opinion</i> , 2018, 34, 1201-1207.	1.9	9
14	Geoeidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients' data. <i>Turkish Journal of Medical Sciences</i> , 2020, 44, 281-290.	0.9	9
15	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 532-536.	0.8	8
16	Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study. <i>Rheumatology International</i> , 2020, 40, 933-940.	3.0	6
17	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1615-1623.	0.9	6
18	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: Treasure real-life data. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	6

#	ARTICLE	IF	CITATIONS
19	Blood group $\alpha^{\circ}$ ™ may have a possible modifier effect on familial Mediterranean fever and blood group $\alpha^{\circ}$ ™ may be associated with colchicine resistance. <i>Biomarkers in Medicine</i> , 2018, 12, 565-572.	1.4	5
20	Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. <i>Rheumatology</i> , 2022, 61, e267-e269.	1.9	5
21	Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 156-158.	0.9	4
22	Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia. <i>Rheumatology International</i> , 2019, 39, 1045-1051.	3.0	4
23	Relationships Between Physical Activity Level, Health-Related Fitness, Academic Achievement, and Academic Self-Concept. <i>Eğitim Ve Bilim</i> , 0, , .	0.3	3
24	The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?. <i>Internal and Emergency Medicine</i> , 2022, 17, 743-751.	2.0	3
25	Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience. <i>Lupus</i> , 2022, 31, 1147-1156.	1.6	3
26	The frequency of Achilles and plantar calcaneal spurs in gout patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1841-1848.	0.9	2
27	AB0706™...Ankylosing spondylitis patients with uveitis had better adalimumab retention rate: hur-bio real life results. , 2017, , .		1
28	Familial Mediterranean Fever: New Insights Into Cancer Immunoprevention? Comment on the Article by Brenner et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 1167-1167.	5.6	1
29	Some concerns from Turkey. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e15-e15.	0.9	1
30	Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. <i>Acta Medica</i> , 0, 52, 4-6.	0.2	1
31	AB0200™...TRENDS IN THE CHOICE OF FIRST BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HUR-BIO REAL-LIFE REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1124.2-1124.	0.9	1
32	POS1378™...COMPARISON OF DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS AND PATIENTS WITH AXIAL SPONDYLOARTHRITIS ACCOMPANYING FAMILIAL MEDITERRANEAN FEVER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 971.1-971.	0.9	1
33	OP0125™...TOFACITINIB IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: EFFICACY AND SAFETY ANALYSIS FROM TREASURE REAL-LIFE DATA. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 69.1-70.	0.9	1
34	Iliac artery aneurysm in Behçet™s syndrome: collaborative management is essential. <i>Rheumatology</i> , 2021, 60, iii32-iii34.	1.9	1
35	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	3.0	1
36	Mediastinal mass in a patient with rheumatoid arthritis: lymphoid cystic thymic hyperplasia. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab049.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Frequency of Respiratory Syncytial Virus Infection Among Patients Hospitalized for Influenza-like Diseases and its Impact on Mortality: Prospective, Multi-center Real Life Results. <i>Flora: the Journal of Infectious Diseases and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi</i> , 2018, 23, 172-178.	0.1	1
38	AB0745â€¦REAL-LIFE EXPERIENCE FOR SECUKINUMAB IN PSORIATIC ARTHRITIS FROM HURBio-PsA DATABASE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1669-1670.	0.9	1
39	SAT0367â€¦EXTRA-ARTICULAR MANIFESTATIONS IN EARLY AXIAL SPONDYLOARTHRITIS: WHAT IS THEIR FREQUENCY? A SYSTEMATIC LITERATURE REVIEW INCLUDING 2854 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1130.1-1131.	0.9	1
40	Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	1
41	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 852-858.	0.8	1
42	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 196-196.	0.8	1
43	AB0641â€¦Comparing the Characteristics of Adult and Pediatric Patients with Polyarteritis Nodosa. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1113.2-1114.	0.9	0
44	SAT0567â€¦Demographic, Clinic and Laboratory Features of 755 Patients with Neonatal Lupus Erythematosus: Systematic Review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 874.2-874.	0.9	0
45	AB0471â€¦Wide heterogeneity in treatment protocols and inappropriate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases. , 2017, , .		0
46	FRI0342â€¦Distribution of vasculitides in eastern mediterranean: results of a prospective cohort. , 2017, , .		0
47	THU0548â€¦Psoriasis in patients with familial mediterranean fever. , 2017, , .		0
48	Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. <i>Rheumatology</i> , 2019, 58, 925-925.	1.9	0
49	THU0565â€¦COMPARISON OF SURVIVAL RATES AMONG SUBGROUPS OF PATIENTS EVALUATED FOR FEVER OF UNKNOWN ORIGIN. , 2019, , .		0
50	SAT0214â€¦CLINICAL FEATURES OF ANEURYSMAL BEHÇET DISEASE. , 2019, , .		0
51	FRI0595â€¦MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?. , 2019, , .		0
52	OP0168â€¦DERIVATION AND VALIDATION OF A NEW STILL ACTIVITY SCORE (SAS). , 2019, , .		0
53	THU0287â€¦ANEURYSM IN BEHÇET DISEASE: MANAGEMENT, PROGNOSIS AND MORTALITY. , 2019, , .		0
54	THU0387â€¦ENTEROPATHIC ARTHRITIS PATIENTS UNDER BDMARD TREATMENTS HAD FREQUENTLY RADIOGRAPHIC SACROILIITIS: HUR-BIO REAL LIFE RESULTS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis. British Journal of Dermatology, 2021, 184, 1202-1203.	1.5	0
56	Successful treatment of penile Mondorâ€™s disease with infliximab in a patient with Behçetâ€™s disease. Rheumatology, 2021, 60, e400-e401.	1.9	0
57	POS0633â€¦DURATION OF STARTING bDMARDs ARE ALMOST 3 TIMES LONGER IN RA PATIENTS THAN PsA PATIENTS: HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2021, 80, 554.2-555.	0.9	0
58	POS0931â€¦RETENTION RATE AND TREATMENT RESPONSE OF BIOLOGICAL AGENTS IN ADVANCED SPINAL ANKYLOSIS AND BAMBOO SPINE: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 728.2-729.	0.9	0
59	POS1070â€¦ANXIETY IN PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM THE HUR-BIO BIOLOGIC REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 814-814.	0.9	0
60	AB0347â€¦RENAL BIOPSY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: IS IT ONLY LUPUS NEPHRITIS?. Annals of the Rheumatic Diseases, 2021, 80, 1198.2-1199.	0.9	0
61	POS0568â€¦OBESITY RATES AND BMI ARE SIMILAR IN AGE AND SEX MATCHED RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 518.3-519.	0.9	0
62	POS0793â€¦PREDICTORS OF END STAGE RENAL DISEASE IN THE RENAL BIOPSY PROVEN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 648.3-649.	0.9	0
63	POS1004â€¦BOTH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS HAVE STRONG FAMILY HISTORIES. Annals of the Rheumatic Diseases, 2021, 80, 770.2-771.	0.9	0
64	AB0201â€¦CHANGES IN THE PRESCRIPTION PATTERNS OF THE SECOND-LINE BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HUR-BIO REAL-LIFE REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 1124.3-1125.	0.9	0
65	AB0535â€¦PRESCRIPTION PATTERNS OF THE SECOND BIOLOGIC DMARD IN PSORIATIC ARTHRITIS THROUGH THE LAST DECADE: HURBIO-PsA REAL LIFE EXPERIENCE. Annals of the Rheumatic Diseases, 2021, 80, 1299.1-1299.	0.9	0
66	POS0251â€¦ARE CLINICAL FEATURES AND OUTCOMES OF ANCA (+) EGPA PATIENTS DIFFERENT FROM ANCA NEGATIVE ONES?. Annals of the Rheumatic Diseases, 2021, 80, 347.2-348.	0.9	0
67	POS0255â€¦IMPACT OF PLASMA EXCHANGE (PLEX) IN SEVERE ANCA-ASSOCIATED VASCULITIS (AAV): A REAL-LIFE DATA FROM A PROSPECTIVE COHORT. Annals of the Rheumatic Diseases, 2021, 80, 350.1-350.	0.9	0
68	c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature. Ulusal Romatoloji Dergisi, 2021, 13, 88-90.	0.0	0
69	AB0562â€¦Demographic Characteristics and Distribution of The Vasculitides Frequencies: A Real- Life Experience of Vasculitis Center from Eastern Mediterranean. Annals of the Rheumatic Diseases, 2016, 75, 1096.4-1097.	0.9	0
70	SAT0594â€¦Which one is more valuable for diagnosis of adult onset stillâ€™s disease? solely neutrophilia or leukocytosis with neutrophilia?. , 2018, , .		0
71	SAT0608â€¦How to differentiate adult onset stillâ€™s disease from overall other causes of fever of unknown origin: results of a prospective study from a tertiary referral centre. , 2018, , .		0
72	AB1140â€¦Comparison of cut-off values for ferritin to discriminate adult onset stillâ€™s disease from other causes of fever of unknown origin: results of a prospective study. , 2018, , .		0



#	ARTICLE	IF	CITATIONS
91	Comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 128, 8.	0.8	0
92	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 196.	0.8	0
93	Can we predict transition from psoriasis to psoriatic arthritis?. Ulusal Romatoloji Dergisi, 2021, 13, 121-128.	0.0	0
94	The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results. Ulusal Romatoloji Dergisi, 2021, 13, 107-115.	0.0	0
95	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0